FDA approval pathways: the 505b2
Pharmaceutical innovation stems from a variety...
Vici can now export and import DEA schedule 1-5 controlled substances to support clinical development
Vici Health Sciences, a customer-focused...
Nitrosamine risk evaluation and testing, what’s next?
Nitrosamine compounds have long been considered...
Creating Formulation Intellectual Property during Drug Development – FAQ
Why must companies consider formulation patents?...
CMO versus CDMO: what’s the difference and how this decision is make or break for early phase drug development programs
Choosing the right organization to develop drugs...
Focusing on medicine for patients with swallowing difficulties
Vici Health Sciences, an innovative formulation...
Vici now offers cGMP API and intermediates synthesis services to support phase 1 clinical and GLP nonclinical studies
Vici Health Sciences, a Maryland-based CDMO is...
High quality formulation development upfront saves drug developers valuable time and money
Drug development leaders must consider...
The Importance of Formulation Development in Successful Drug Development
Formulation development is a critical part of...
6725 Santa Barbara Court,
Elkridge, MD 21075